Brief: Inozyme Pharma Reports Q2 2021 Financial Results

Inozyme Pharma

11/08/2021 11:12

Aug 11 (Reuters) - Inozyme Pharma Inc  INZY.O :
    * INOZYME PHARMA REPORTS Q2 2021 FINANCIAL RESULTS AND
PROVIDES
BUSINESS HIGHLIGHTS
    * EXPECT TO ENROLL PATIENTS IN PHASE 1/2 CLINICAL TRIALS IN
ENPP1
DEFICIENCY AND ABCC6 DEFICIENCY IN Q4 2021
    * CASH, CASH EQUIVALENTS, AND INVESTMENTS EXPECTED TO
SUPPORT
CONTINUED OPERATIONS INTO Q4 OF2022
    * Q2 LOSS PER SHARE $0.53
    * EXPECT TO REPORT PRELIMINARY BIOMARKER AND SAFETY DATA
FROM
PHASE 1/2 CLINICAL TRIALS IN FIRST HALF OF 2022

Source text for Eikon:  ID:nGNX91rW5d 
Further company coverage:  INZY.O 

 ((Reuters.Briefs@thomsonreuters.com;))